San Francisco-based Jaguar Animal Health(JAGX) helps with doggie diarrhea—there I said it. But, I love the Jag. The stock had a tough 2015 after an IPO in May and normal selling. It is a bit of a cautionary note to CEO's who bring the company public without explosive revenue or bullet-proof industry multiple. The yellow signs come out when a skinny trader doesn't have enough volume to absorb the selling pressure. The IR person at the company has some work to do in 2015, but I love the Jag and I don't know why. I do know they need a market awareness effort for Q1. I like the company because it cures many issues for animals, and this 20B market is huge + I love dogs.
Jaguar Animal Health, Inc., a development-stage animal health company, focuses on developing and commercializing gastrointestinal products for companion and production animals. The lead prescription drug product candidate includes Canalevia, a canine-specific formulation of Crofelemer for the treatment of CID and general acute watery diarrhea in dogs.
The company is also developing Crofelemer to treat acute colitis in horses and general acute watery diarrhea in cats; Neonorm, an enteric-coated tablet for scours in preweaned dairy calves, as well as other animal species, such as horses, goats, and sheep; and other product candidates, including Virend and NP-500. The company was founded in 2013 and is headquartered in San Francisco, California. Jaguar Animal Health, Inc. is a subsidiary of Napo Pharmaceuticals, Inc.
Diarrhea is one of the most common reasons for veterinary office visits for dogs and is the second most common reason for visits to the veterinary emergency room, yet there are no FDA-approved anti-secretory agents to treat canine diarrhea.
According to the American Veterinary Medical Association, there were approximately 70 million dogs in the United States in 2012. Jaguar estimates that in the U.S., veterinarians see approximately six million annual cases of acute and chronic diarrhea in canines. Devastating dehydration can occur rapidly for the animal, and the lack of control in urban settings where owners don’t have easy access to outdoor facilities is a significant problem for families with dogs.
“The design, enrollment criteria, endpoints, and powering assumptions for our pivotal Canalevia™ study are based on our experience and success with the Canalevia™ proof-of-concept study we completed earlier this year,” stated Lisa Conte, Jaguar’s president and CEO. “We are confident that Canalevia™ will be a new tool in the treatment of canine acute diarrhea—and the coincident health and quality of life issues for both dogs and their owners.”
Stocks down in 2015 are ones I watch early in 2016. JAGX had a rough 2015 after the May IPO but the current price tag (20M Valuation) makes me think this is an Emerging growth story to watch, and there I did it. I will be following dog poop for Q1 2016 !! Send me a pooper scooper.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer